| Ytd | 59.80% | |
| 1y | 8.11% |
| Open | 9.72 | Prev Close | 9.57 | Low | 9.28 | High | 10.01 | Mkt Cap | 308.22M |
| Vol | 949.74K | Avg Vol | 1.12M | EPS | -1.34 | P/E | -7.06 | Forward P/E | -1.40 |
| Beta | 3.37 | Short Ratio | 1.37 | Inst. Own | 66.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 7.29 | 200-d Avg | 6.61 | 1yr Est | 29.14 |
SGMT News
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc.
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in
Sagimet Biosciences receives a Buy rating, driven by denifanstat's potential in MASH and acne, despi
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clini
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifa
Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investor
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in
Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced
The biopharma company confirmed it's still aiming at the United States' acne-treatment market.
SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cli
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to i
Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus reco
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cli
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cli
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu
Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company a
On Thursday, 369 companies hit new 52-week lows.
On Wednesday, 311 stocks hit new 52-week lows.
On Monday, 369 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
Wednesday's session saw 150 companies set new 52-week lows.